Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical Trials

The increased research activity aiming at improved delivery of pharmaceutical molecules indicates the expansion of the field. An efficient therapeutic delivery approach is based on the optimal choice of drug-carrying vehicle, successful targeting, and payload release enabling the site-specific accum...

Full description

Bibliographic Details
Main Authors: Denis V. Voronin, Anatolii A. Abalymov, Yulia I. Svenskaya, Maria V. Lomova
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/22/17/9149
id doaj-f6ca6aabaf144c96848c6ff4ffdbb4a8
record_format Article
spelling doaj-f6ca6aabaf144c96848c6ff4ffdbb4a82021-09-09T13:46:46ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-08-01229149914910.3390/ijms22179149Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical TrialsDenis V. Voronin0Anatolii A. Abalymov1Yulia I. Svenskaya2Maria V. Lomova3Science Medical Center, Saratov State University, Astrakhanskaya St. 83, 410012 Saratov, RussiaScience Medical Center, Saratov State University, Astrakhanskaya St. 83, 410012 Saratov, RussiaScience Medical Center, Saratov State University, Astrakhanskaya St. 83, 410012 Saratov, RussiaScience Medical Center, Saratov State University, Astrakhanskaya St. 83, 410012 Saratov, RussiaThe increased research activity aiming at improved delivery of pharmaceutical molecules indicates the expansion of the field. An efficient therapeutic delivery approach is based on the optimal choice of drug-carrying vehicle, successful targeting, and payload release enabling the site-specific accumulation of the therapeutic molecules. However, designing the formulation endowed with the targeting properties in vitro does not guarantee its selective delivery in vivo. The various biological barriers that the carrier encounters upon intravascular administration should be adequately addressed in its overall design to reduce the off-target effects and unwanted toxicity in vivo and thereby enhance the therapeutic efficacy of the payload. Here, we discuss the main parameters of remote-controlled drug delivery systems: (i) key principles of the carrier selection; (ii) the most significant physiological barriers and limitations associated with the drug delivery; (iii) major concepts for its targeting and cargo release stimulation by external stimuli in vivo. The clinical translation for drug delivery systems is also described along with the main challenges, key parameters, and examples of successfully translated drug delivery platforms. The essential steps on the way from drug delivery system design to clinical trials are summarized, arranged, and discussed.https://www.mdpi.com/1422-0067/22/17/9149drug delivery systemsactive targeting in vivophysiological barriersremote navigationmagnetic fieldselectric fields
collection DOAJ
language English
format Article
sources DOAJ
author Denis V. Voronin
Anatolii A. Abalymov
Yulia I. Svenskaya
Maria V. Lomova
spellingShingle Denis V. Voronin
Anatolii A. Abalymov
Yulia I. Svenskaya
Maria V. Lomova
Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical Trials
International Journal of Molecular Sciences
drug delivery systems
active targeting in vivo
physiological barriers
remote navigation
magnetic fields
electric fields
author_facet Denis V. Voronin
Anatolii A. Abalymov
Yulia I. Svenskaya
Maria V. Lomova
author_sort Denis V. Voronin
title Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical Trials
title_short Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical Trials
title_full Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical Trials
title_fullStr Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical Trials
title_full_unstemmed Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical Trials
title_sort key points in remote-controlled drug delivery: from the carrier design to clinical trials
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2021-08-01
description The increased research activity aiming at improved delivery of pharmaceutical molecules indicates the expansion of the field. An efficient therapeutic delivery approach is based on the optimal choice of drug-carrying vehicle, successful targeting, and payload release enabling the site-specific accumulation of the therapeutic molecules. However, designing the formulation endowed with the targeting properties in vitro does not guarantee its selective delivery in vivo. The various biological barriers that the carrier encounters upon intravascular administration should be adequately addressed in its overall design to reduce the off-target effects and unwanted toxicity in vivo and thereby enhance the therapeutic efficacy of the payload. Here, we discuss the main parameters of remote-controlled drug delivery systems: (i) key principles of the carrier selection; (ii) the most significant physiological barriers and limitations associated with the drug delivery; (iii) major concepts for its targeting and cargo release stimulation by external stimuli in vivo. The clinical translation for drug delivery systems is also described along with the main challenges, key parameters, and examples of successfully translated drug delivery platforms. The essential steps on the way from drug delivery system design to clinical trials are summarized, arranged, and discussed.
topic drug delivery systems
active targeting in vivo
physiological barriers
remote navigation
magnetic fields
electric fields
url https://www.mdpi.com/1422-0067/22/17/9149
work_keys_str_mv AT denisvvoronin keypointsinremotecontrolleddrugdeliveryfromthecarrierdesigntoclinicaltrials
AT anatoliiaabalymov keypointsinremotecontrolleddrugdeliveryfromthecarrierdesigntoclinicaltrials
AT yuliaisvenskaya keypointsinremotecontrolleddrugdeliveryfromthecarrierdesigntoclinicaltrials
AT mariavlomova keypointsinremotecontrolleddrugdeliveryfromthecarrierdesigntoclinicaltrials
_version_ 1717760250141999104